Astrazeneca Pharma India Ltd vs Gland Pharma Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 12, 2026

Key Highlights

The Latest Trading Price of Astrazeneca Pharma India Ltd is ₹ 8308 as of 12 May 15:30 . The P/E Ratio of Astrazeneca Pharma India Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Gland Pharma Ltd changed from 40.7 on March 2021 to 37.5 on March 2025 . This represents a CAGR of -1.62% over 5 years The Market Cap of Astrazeneca Pharma India Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Gland Pharma Ltd changed from ₹ 40535 crore on March 2021 to ₹ 26232 crore on March 2025 . This represents a CAGR of -8.34% over 5 years The revenue of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Gland Pharma Ltd for the Dec '25 is ₹ 1758 crore as compare to the Sep '25 revenue of ₹ 1571 crore. This represent the growth of 11.93% The ebitda of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Gland Pharma Ltd for the Dec '25 is ₹ 473.7 crore as compare to the Sep '25 ebitda of ₹ 398.05 crore. This represent the growth of 19.01% The net profit of Astrazeneca Pharma India Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Gland Pharma Ltd changed from ₹ 143.76 crore to ₹ 261.48 crore over 7 quarters. This represents a CAGR of 40.75% The Dividend Payout of Astrazeneca Pharma India Ltd changed from 5.36 % on March 2021 to 69.12 % on March 2025 . This represents a CAGR of 66.76% over 5 yearsThe Dividend Payout of Gland Pharma Ltd changed from 31.57 % on March 2024 to 27.22 % on March 2025 . This represents a CAGR of -7.14% over 2 years .

About Astrazeneca Pharma India Ltd

AstraZeneca Pharma India Limited (APIL) was incorporated on July 11, 1979.
The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company.
The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology. AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital.
Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company.

About Gland Pharma Ltd

Gland Pharma Limited was incorporated as Gland Pharma Private Limited', a private limited company on March 20, 1978 and was granted the certificate of incorporation by Registrar of Companies, Andhra Pradesh at Hyderabad.
Subsequently, the name of the Company was changed to Gland Pharma Limited' and a fresh certificate of incorporation dated April 25, 1995 was issued by the Registrar of Companies, Andhra Pradesh at Hyderabad.
The Company is primarily engaged in manufacturing injectable formulations. Established in Hyderabad, India, Company has evolved into a prominent entity in the global generic injectables market, with operations extending to over 60 countries including the United States, Europe, Canada, Australia, and India.
Primarily functioning under a B2B model, the company provides comprehensive services such as contract development, dossier compilation, technology transfer, and manufacturing across various delivery systems.

FAQs for the comparison of Astrazeneca Pharma India Ltd and Gland Pharma Ltd

Which company has a larger market capitalization, Astrazeneca Pharma India Ltd or Gland Pharma Ltd?

Market cap of Astrazeneca Pharma India Ltd is 20,770 Cr while Market cap of Gland Pharma Ltd is 30,844 Cr

What are the key factors driving the stock performance of Astrazeneca Pharma India Ltd and Gland Pharma Ltd?

The stock performance of Astrazeneca Pharma India Ltd and Gland Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Astrazeneca Pharma India Ltd and Gland Pharma Ltd?

As of May 12, 2026, the Astrazeneca Pharma India Ltd stock price is INR ₹8308.3. On the other hand, Gland Pharma Ltd stock price is INR ₹1872.15.

How do dividend payouts of Astrazeneca Pharma India Ltd and Gland Pharma Ltd compare?

To compare the dividend payouts of Astrazeneca Pharma India Ltd and Gland Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.